Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...
Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief commercial ...
Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...
Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The ...
3don MSN
Moderna Inc.’s stock jumped 5% early Thursday, after the company’s third-quarter earnings showed an unexpected profit and ...
The Cambridge-based company’s latest COVID shot was approved three weeks earlier than last year, according to a statement ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Investor's Business Daily on MSN3d
Moderna Slashes Hefty Premarket Gain With A Beat That's 'Not A Beat'Moderna crushed third-quarter expectations on Thursday and turned around a surprise profit. But Moderna stock pulled back ...
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...
Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...
Moderna reported better third-quarter results than expected Thursday morning, as the vaccine maker reported a surprise profit for the period amid its efforts to cut costs and $1.8 billion in sales of ...
In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback